0001104659-20-115710.txt : 20201016
0001104659-20-115710.hdr.sgml : 20201016
20201016180534
ACCESSION NUMBER: 0001104659-20-115710
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201014
FILED AS OF DATE: 20201016
DATE AS OF CHANGE: 20201016
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Esposito Pamela
CENTRAL INDEX KEY: 0001744425
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38596
FILM NUMBER: 201244850
MAIL ADDRESS:
STREET 1: C/O REPLIMUNE GROUP, INC.
STREET 2: 18 COMMERCE WAY
CITY: WOBURN
STATE: MA
ZIP: 01801
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Replimune Group, Inc.
CENTRAL INDEX KEY: 0001737953
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 822082553
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0331
BUSINESS ADDRESS:
STREET 1: 500 UNICORN PARK
CITY: WOBURN
STATE: MA
ZIP: 01801
BUSINESS PHONE: (781) 222-9600
MAIL ADDRESS:
STREET 1: 500 UNICORN PARK
CITY: WOBURN
STATE: MA
ZIP: 01801
4
1
a4.xml
4
X0306
4
2020-10-14
0
0001737953
Replimune Group, Inc.
REPL
0001744425
Esposito Pamela
C/O REPLIMUNE GROUP, INC.
500 UNICORN PARK
WOBURN
MA
01801
0
1
0
0
Chief Business Officer
Common Stock
2020-10-14
4
M
0
16000
1.01
A
128700
D
Common Stock
2020-10-14
4
S
0
7000
30.15
D
121700
D
Common Stock
2020-10-14
4
S
0
9000
35.04
D
112700
D
Employee Stock Option (right to buy)
1.01
2020-10-14
4
M
0
16000
0
D
2025-11-01
Common Stock
16000
128203
D
The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on June 15, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended.
The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.57.
The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.20.
Following the sales reported on this Form 4, the reporting person continues to beneficially own 112,700 shares of the Issuer's common stock. The reporting person also holds options to acquire an aggregate of 577,146 shares of the Issuer's common stock, 384,273 of which are exercisable as of the date hereof.
The reporting person was granted an option to purchase 149,203 shares of the Issuer's common stock on November 1, 2015. All of the shares underlying the stock option have vested and are exercisable as of the date hereof.
/s/ Jean Franchi, attorney-in-fact
2020-10-16